Rationale and design of a pilot randomized controlled trial to assess the role of intravenous ferric carboxymaltose in Asian patients with heart failure (PRACTICE-ASIA-HF).

Journal: ESC heart failure
Published Date: Dec 16, 2015

Abstract

AIMS: Iron deficiency (ID) is highly prevalent in patients with heart failure (HF) worldwide regardless of haemoglobin levels. Results from therapeutic trials of intermittently dosed intravenous (i.v.) iron are promising in the ambulatory Caucasian population with HF with reduced left ventricular ejection fraction, although evidence is scarce in Asia. The Pilot Randomized Controlled Trial to Assess the Role of Intravenous Ferric Carboxymaltose in Asian Patients with Heart Failure aims to assess the effect of single-dose i.v. ferric carboxymaltose (FCM) in a multi-ethnic Asian population with HF and ID.

Authors

  • Tee Joo Yeo
    National University Heart Centre Singapore National University Health System Singapore.
  • Poh Shuan Daniel Yeo
    Tan Tock Seng Hospital Apex Heart Clinic Gleneagles Hospital Singapore.
  • Farid Abdul Hadi
    Vifor Pharma Asia Pacific Singapore.
  • Timothy Cushway
    Vifor Pharma Asia Pacific Singapore.
  • Kim Yee Lee
    National University Heart Centre Singapore National University Health System Singapore.
  • Bee Choo Tai
    Saw Swee Hock School of Public Health National University of Singapore Singapore.
  • Carolyn S P Lam
    Duke-NUS Medical School, 8 College Rd, Singapore 169857, Singapore.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals